MARKET

CSTL

CSTL

Castle Biosciences
NASDAQ
20.52
+0.45
+2.24%
After Hours: 20.52 0 0.00% 16:39 03/21 EDT
OPEN
19.86
PREV CLOSE
20.07
HIGH
21.01
LOW
19.76
VOLUME
605.75K
TURNOVER
--
52 WEEK HIGH
35.84
52 WEEK LOW
16.97
MARKET CAP
585.11M
P/E (TTM)
32.90
1D
5D
1M
3M
1Y
5Y
1D
Castle Biosciences management to meet with Stephens
TipRanks · 2d ago
Weekly Report: what happened at CSTL last week (0310-0314)?
Weekly Report · 5d ago
Weekly Report: what happened at CSTL last week (0303-0307)?
Weekly Report · 03/10 10:52
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Barchart · 03/07 06:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Castle Biosciences (CSTL), AbCellera Biologics (ABCL) and Apellis Pharmaceuticals (APLS)
TipRanks · 03/03 12:31
Castle Biosciences (CSTL) Gets a Buy from Scotiabank
TipRanks · 03/03 12:30
Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)
TipRanks · 03/03 11:00
Weekly Report: what happened at CSTL last week (0224-0228)?
Weekly Report · 03/03 10:51
More
About CSTL
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Webull offers Castle Biosciences Inc stock information, including NASDAQ: CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.